Skip to main content

Skytrofa Side Effects

Generic name: lonapegsomatropin

Medically reviewed by Last updated on Jan 31, 2024.

Note: This document contains side effect information about lonapegsomatropin. Some dosage forms listed on this page may not apply to the brand name Skytrofa.

Applies to lonapegsomatropin: subcutaneous powder for solution.

Serious side effects of Skytrofa

Along with its needed effects, lonapegsomatropin (the active ingredient contained in Skytrofa) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking lonapegsomatropin:

More common

Incidence not known

Other side effects of Skytrofa

Some side effects of lonapegsomatropin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to lonapegsomatropin: subcutaneous injection.


The most common adverse events were viral infection, pyrexia, cough, and nausea and vomiting.[Ref]


Very common (10% or more): Viral infection (15%)[Ref]


Very common (10% or more): Pyrexia (15%)

Frequency not reported: Increased mortality in patients with acute critical illness, sudden death in pediatric patients with Prader-Willi syndrome[Ref]


Very common (10% or more): Nausea and vomiting (11%)

Common (1% to 10%): Diarrhea, abdominal pain

Frequency not reported: Pancreatitis[Ref]


Common (1% to 10%): Hemorrhage[Ref]


Common (1% to 10%): Arthralgia and arthritis

Frequency not reported: Slipped capital femoral epiphysis in pediatric patients, progression of preexisting scoliosis in pediatric patients[Ref]


Frequency not reported: Severe hypersensitivity[Ref]


Very common (10% or more): Cough (11%)[Ref]

Nervous system

Frequency not reported: Intracranial hypertension[Ref]


Frequency not reported: Increased risk of neoplasms[Ref]


Frequency not reported: Glucose intolerance and diabetes mellitus, fluid retention, elevated phosphate and alkaline phosphatase levels[Ref]


Frequency not reported: Hypoadrenalism, hypothyroidism[Ref]


1. (2021) "Product Information. Skytrofa (lonapegsomatropin)." Ascendis Pharma, Inc.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.